Table 2.
BRM polymorphisms and overall survival in advanced stage non-small cell lung cancer
| Poly- morphism |
Category | PM Cohort (N=548) |
BR.24 Conventional Arm (N=109) |
BR.24 Experimental Arm (N=110) |
BR.24 All Patients (N=219) |
||||
|---|---|---|---|---|---|---|---|---|---|
| % | aHR (95%CI)1 | % | aHR (95%CI)2 | % | aHR (95%CI)2 | % | aHR (95%CI)2 | ||
| Wild-type | 29% | Reference | 30% | Reference | 27% | Reference | 28% | Reference | |
| Heterozygote | 48% | 1.60 (1.2–2.2) | 43% | 2.81 (1.5–5.4) | 49% | 2.21 (1.1–4.5) | 45% | 2.75 (1.7–4.4) | |
| BRM -741 | Homozygote | 23% | 2.49 (1.9–3.3) | 29% | 5.52 (2.7–11.2) | 25% | 3.91 (1.8–8.4) | 27% | 4.98 (3.0–8.3) |
| P value3 | <0.001 | <0.001 | 0.002 | <0.001 | |||||
| Minor allele frequency |
46% | 50% | 49% | 50% | |||||
| Wild-type | 34% | Reference | 28% | Reference | 30% | Reference | 29% | Reference | |
| Heterozygote | 44% | 1.18 (0.9–1.5) | 55% | 3.14 (1.6–6.0) | 46% | 2.01 (1.1–3.8) | 50% | 2.53 (1.6–3.9) | |
| BRM -1321 | Homozygote | 22% | 1.99 (1.5–2.7) | 18% | 7.64 (3.5–16.7) | 24% | 3.54 (1.8–7.1) | 21% | 4.98 (3.0–8.3) |
| P value3 | <0.001 | <0.001 | 0.002 | <0.001 | |||||
| Minor allele Frequency |
44% | 44% | 46% | 45% | |||||
| Combined Poly- morphisms |
Double Wild-type | 21% | Reference | 19% | Reference | 18% | Reference | 19% | Reference |
| No homozygote | 47% | 1.40 (1.0–1.8) | 46% | 2.90 (1.3–6.7) | 48% | 3.46 (1.3–9.3) | 47% | 3.40 (1.8–6.3) | |
| One Homozygote | 21% | 2.17 (1.6–3.1) | 24% | 5.05 (2.09–12.3) | 18% | 9.26 (3.2–27.0) | 21% | 6.62 (3.4–13.1) | |
| Two homozygotes | 12% | 2.74 (1.9–4.0) | 11% | 16.8 (6.0–46.7) | 15% | 6.36 (2.2–19.1) | 13% | 8.97 (3.3–18.5) | |
| P value3 | <0.001 | <0.001 | 0.001 | <0.001 | |||||
1
adjusted for sex, stage, ECOG performance status at diagnosis, number. of lines of systemic therapy received, and prior surgical resection of lung primary or site of oligometastases;
2
adjusted for sex, stage, ECOG performance status, weight loss, and time from diagnosis to randomization; in the “all patients” analysis, there was also stratification by treatment arm.
3
p-values are from Cox proportional hazard models comparing BRM polymorphisms and survival.
PM – Princess Margaret